Meeting
2023 ASCO Annual Meeting
Endpoints reported in phase 3 randomized clinical trials at ASCO 2022.
Authors
Laure-Anne Marie Nicole Teuwen
Department of oncology, Antwerp University Hospital, Edegem, Belgium
Laure-Anne Marie Nicole Teuwen , Joanna Alyse Young , Maria Teresa Bourlon , Eva Segelov , Hans Prenen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Care Delivery and Regulatory Policy
Track
Care Delivery and Quality Care
Sub Track
Clinical Research Design
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1570)
DOI
10.1200/JCO.2023.41.16_suppl.1570
Abstract #
1570
Poster Bd #
164
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Effect of early integration of specialized palliative care into standard oncologic treatment on the quality of life of patients with advanced head and neck cancers: A phase III randomized controlled trial.
First Author: Pankaj Singhai
First Author: Kohei Shitara
Poster
2024 ASCO Annual Meeting
Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.
First Author: Melissa Lynne Johnson
Poster
2024 ASCO Annual Meeting
Paclitaxel oral solution versus paclitaxel injection as second-line therapy in advanced gastric cancer: A randomized, open-label, non-inferiority phase 3 trial.
First Author: Jin Li